NDC product
KEYTRUDA QLEX
NDC 0006-3083 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-3083 |
|---|---|
| Proprietary name | KEYTRUDA QLEX |
| Nonproprietary name | pembrolizumab and berahyaluronidase alfa-pmph |
| Substances | PEMBROLIZUMAB, BERAHYALURONIDASE ALFA |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761467 |
| Pharmacologic classes | Endoglycosidase [EPC], Glycoside Hydrolases [CS], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA] |
| Marketing start | Sep 19, 2025 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: